Cargando…

THER-13. IMMUNOTHERAPY VERSUS STANDARD OF CARE IN MELANOMA BRAIN METASTASES WITH KNOWN BRAF STATUS

BACKGROUND: A mutation of the BRAF protein is seen in approximately 50% of melanoma patients. Immune checkpoint inhibitors (ICI) are standard therapy in melanoma patients independent of a patient’s BRAF status. The primary objective of this study is to investigate the impact of BRAF status in patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barnett, Addison, Sagar, Soumya, Lauko, Adam, Wei, Wei, Chao, Samuel, Peereboom, David, Stevens, Glen, Angelov, Lilyana, Yu, Jennifer, Murphy, Erin, Mohammadi, Alireza, Suh, John, Barnett, Gene, Ahluwalia, Manmeet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213394/ http://dx.doi.org/10.1093/noajnl/vdz014.056

Ejemplares similares

THER-10. IMPACT OF BRAF MUTATIONAL STATUS ON THE EFFICACY OF IMMUNOTHERAPY FOR MELANOMA BRAIN METASTASES
por: Lauko, Adam, et al.
Publicado: (2019)

THER-02. IMPACT OF SYSTEMIC THERAPY IN MELANOMA BRAIN METASTASIS
por: Sagar, Soumya, et al.
Publicado: (2019)

THER-09. IMPACT OF KRAS MUTATION STATUS ON THE EFFICACY OF IMMUNOTHERAPY IN LUNG CANCER BRAIN METASTASES
por: Lauko, Adam, et al.
Publicado: (2019)

THER-16. EFFICACY OF UPFRONT IMMUNE CHECKPOINT INHIBITORS IN LUNG CANCER BRAIN METASTASIS
por: Barnett, Addison, et al.
Publicado: (2019)

THER-14. INFLUENCE OF CLINICAL PARAMETERS ON THE EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER BRAIN METASTASES (NSCLCBM)
por: Lauko, Adam, et al.
Publicado: (2019)

Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2021)

Author Correction: Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2022)

TRLS-05. EARLY RESULTS FROM A PROSPECTIVE PHASE I/II DOSE ESCALATION STUDY OF NEOADJUVANT RADIOSURGERY FOR BRAIN METASTASES
por: Murphy, Erin, et al.
Publicado: (2019)

Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2021)

Author Correction: Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2021)

Author Correction: Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2022)

RADI-25. REPEAT STEREOTACTIC RADIOSURGERY FOR RECURRENT BRAIN METASTASES
por: Krivosheya, Daria, et al.
Publicado: (2019)

RADI-35. AN ANALYSIS OF RESPONSE ENDPOINTS FOR BRAIN METASTASIS PATIENTS TREATED WITH STEREOTACTIC RADIOSURGERY AND PD(L)-1 INHIBITORS
por: Kotecha, Rupesh, et al.
Publicado: (2019)

First follow‐up radiographic response is one of the predictors of local tumor progression and radiation necrosis after stereotactic radiosurgery for brain metastases
por: Sharma, Mayur, et al.
Publicado: (2017)

Medical management of brain metastases
por: Lauko, Adam, et al.
Publicado: (2020)

An Excellent Clinical Outcome with Stereotactic Radiosurgery in a Geriatric Patient with Multiple and Recurrent Brain Metastases
por: Thapa, Bicky, et al.
Publicado: (2017)

THER-06. GENOMIC AND IMMUNE CHARACTERIZATION OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES
por: Vincent, Benjamin, et al.
Publicado: (2019)

First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Tatineni, Vineeth, et al.
Publicado: (2023)

Targeted therapy of brain metastases: latest evidence and clinical implications
por: Di Lorenzo, Rodica, et al.
Publicado: (2017)

An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status
por: Ahluwalia, Manmeet, et al.
Publicado: (2020)

THER-04. THE USE OF AN ADENOSINE A2 AGONIST TO IMPROVE THE PREVENTION AND TREATMENT OF BRAIN METASTASES
por: Grossman, Stuart, et al.
Publicado: (2019)

Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression
por: Alban, Tyler J., et al.
Publicado: (2020)

Targeted Therapy After Brain Radiotherapy for BRAF-Mutated Melanoma With Extensive Ependymal Disease With Prolonged Survival: Case Report and Review of the Literature
por: Abu-Gheida, Ibrahim, et al.
Publicado: (2019)

Veterinary Medicines: Ther Actions and Uses
Publicado: (1883)

Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
por: Tatineni, Vineeth, et al.
Publicado: (2023)

Novel Therapeutic Approaches in Neoplastic Meningitis
por: Khosla, Atulya Aman, et al.
Publicado: (2022)

THER-15. DEVELOPING TUMOR-HOMING CYTOTOXIC HUMAN INDUCED NEURAL STEM CELL THERAPY FOR BRAIN METASTASES
por: Mercer-Smith, Alison, et al.
Publicado: (2019)

THER-07. DEVELOPMENT OF A NEW MOLECULAR PREDICTOR FOR RISK OF BRAIN METASTASES AND EFFICACY OF TARGETED THERAPY IN MELANOMA
por: Colman, Howard, et al.
Publicado: (2019)

Report by ther Chairman of the Scientific Policy Committee
Publicado: (1959)

Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases
por: Tonse, Raees, et al.
Publicado: (2021)

Spatial immunosampling of MRI-defined glioblastoma regions reveals immunologic fingerprint of non-contrast enhancing, infiltrative tumor margins
por: Grabowski, Matthew M., et al.
Publicado: (2023)

TRLS-01. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS (TTFIELDS) FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
por: Mehta, Minesh, et al.
Publicado: (2019)

Laser interstitial thermal therapy for brain metastases
por: Srinivasan, Ethan S, et al.
Publicado: (2021)

First clinical experience with belzutifan in von Hippel–Lindau disease associated CNS hemangioblastoma
por: Dhawan, Andrew, et al.
Publicado: (2022)

30. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
por: Mehta, Minesh P, et al.
Publicado: (2020)

CLRM-10 METIS (EF-25): A PIVOTAL, RANDOMIZED CONTROLLED STUDY OF TUMOR TREATING FIELDS IN PATIENTS WITH 1–10 BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER
por: Mehta, Minesh, et al.
Publicado: (2022)

THER-12. PRECLINICAL EVALUATION OF NERATINIB PLUS T-DM1 IN ORTHOTOPIC PDX MODELS OF HER2-POSITIVE BREAST CANCER BRAIN METASTASES
por: Ni, Jing, et al.
Publicado: (2019)

P-THER-09: Endoscopic ultrasound-guided pelvic abscess drainage
por: Harwani, Yogesh, et al.
Publicado: (2017)

THER-04. IS THERE A ROLE FOR CANNABIDIOL IN THE TREATMENT OF CHILDHOOD BRAIN TUMOURS?
por: Lockwood, George, et al.
Publicado: (2020)

New Ther1-derived SINE Squam3 in scaled reptiles
por: Vassetzky, Nikita S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qf6um84fsvba20sevf8sb0i1hn